IP Library › Granted Patent US 11,096,696
Granted Patent B2
US 11,096,696 · App. 16/245,279 · Granted Aug 24, 2021

Occlusive medical device

Inventors: Steven R. Larsen (Lino Lakes, MN); Daniel H. VanCamp (Elk River, MN); David John Onushko (Minneapolis, MN); Lindsay Marie Godin (Maple Grove, MN)
Assignee: Boston Scientific Scimed, Inc.
A61B17/12122A61B17/0057A61B17/12031A61B17/12113A61B17/12168A61B17/12172A61B17/1219A61B17/12027A61B17/12177A61B2017/00632A61B2017/00862A61B2017/00867A61B2017/1205
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,096,696
App. No.
16/245,279
Granted
Aug 24, 2021
Kind
B2
Abstract

An example occlusive implant is disclosed. The example occlusive implant includes an expandable framework configured to shift between a collapsed configuration and an expanded configuration, an occlusive member disposed along at least a portion of the expandable framework and a sealing member disposed along the occlusive member, wherein the occlusive member includes at least a first cellular tissue growth pathway.

Claims (31)

1. An occlusive implant, comprising:

an expandable framework configured to shift between a collapsed configuration and an expanded configuration; and

an occlusive member disposed along at least a portion of the expandable framework;

wherein the occlusive member includes a plurality of elongated, straight, continuous filaments that form a plurality of discrete elongated, straight, continuous cellular tissue growth pathways,

wherein the pathways extend radially away from a central region of the occlusive member,

wherein the central region of the occlusive member includes a termination member,

wherein at least one of the filaments forming a first cellular growth pathway is coupled to the termination member,

wherein the first cellular growth pathway is continuous between the termination member and an outer edge region of the implant,

wherein at least one of the plurality of elongated, straight, continuous filaments includes a longitudinally extending channel, and wherein the channel is configured to promote cellular tissue growth along its length thereof.

2. The occlusive implant of claim 1 , wherein the plurality of elongated, straight, continuous filaments are woven together.

3. The occlusive implant of claim 1 , wherein the occlusive member includes a monolithic sheet of material.

4. The occlusive implant of claim 3 , wherein the monolithic sheet of material has one or more apertures therein, and wherein the pathways are formed from material extending between the one or more apertures.

5. The occlusive implant of claim 1 , wherein at least two of the plurality of elongated, straight, continuous filaments are coupled together via at least one lateral member.

6. The occlusive implant of claim 1 , wherein the occlusive implant further comprising a second tissue growth pathway positioned adjacent to the first elongated, straight, continuous cellular tissue growth pathway.

7. A medical implant for occluding a left atrial appendage, comprising:

an expandable framework configured to shift between a collapsed configuration and an expanded configuration; and

an occlusive member disposed along at least a portion of the expandable framework, the occlusive member including a central region;

wherein the occlusive member includes a plurality of elongated, straight, continuous filaments that form a plurality of discrete elongated, straight, continuous cellular growth pathways extending radially away from the central region;

wherein each of the cellular growth pathways is configured to promote continuous cellular tissue growth along its length thereof,

wherein at least one of the plurality of elongated, straight, continuous filaments includes a longitudinally extending channel, and wherein the channel is configured to promote cellular tissue growth along its length thereof.

8. The occlusive implant of claim 7 , wherein the plurality of elongated, straight, continuous filaments are woven together.

9. The occlusive implant of claim 7 , wherein the occlusive member includes a monolithic sheet of material.

10. The occlusive implant of claim 9 , wherein the monolithic sheet of material has one or more apertures therein, and wherein the plurality of cellular growth pathways are formed from material extending between the one or more apertures.

11. The occlusive implant of claim 7 , wherein at least two of the plurality of elongated, straight, continuous filaments are coupled together via at least one lateral member.

12. A method for occluding a left atrial appendage, the method comprising:

advancing an occlusive implant to the left atrial appendage, the occlusive implant including:

an expandable framework; and

an occlusive member disposed along at least a portion of the expandable framework,

wherein the occlusive member includes a central region;

wherein the occlusive member includes a plurality of elongated, straight, continuous filaments that form a plurality of discrete elongated, straight, continuous cellular tissue growth pathways coupled to a termination member and extending radially away from the central region; wherein at least one of the plurality of elongated, straight, continuous filaments includes a longitudinally extending channel, and wherein the channel is configured to promote cellular tissue growth along its length thereof, and

expanding the expandable framework within the left atrial appendage.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2019
From: LARSEN, STEVEN R.; VANCAMP, DANIEL H.; ONUSHKO, DAVID JOHN; GODIN, LINDSAY MARIE
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 050336/0492 →
Continuity (2)
Provisional Application 62616515 · Jan 12, 2018
Related Publication 20190216468A1 · Jul 18, 2019